Dexcom
DXCM
$77.98
+7.22%
DexCom, Inc. designs and commercializes continuous glucose monitoring (CGM) systems for diabetic patients, offering an alternative to traditional blood glucose meters. As a market leader in the CGM space, DexCom differentiates itself through its advanced sensor technology and integration with insulin pumps from Insulet and Tandem for automated insulin delivery. The current investor narrative centers on growth acceleration driven by recent FDA clearance for pediatric use of its over-the-counter Stelo monitor, expanding its addressable market, while margin expansion and strong free cash flow generation support the bull case despite competitive pressures.…
DXCM
Dexcom
$77.98
Related headlines
Investment Opinion: Should I buy DXCM Today?
Rating: Buy. DexCom is a high-quality growth company with a strong competitive position in the CGM market, supported by expanding margins and a robust balance sheet. The consensus analyst rating is Strong Buy with an average target of $85.46, implying 17.5% upside. Supporting Evidence: The trailing PE of 31.0x is elevated but justified by a PEG ratio of 0.67, indicating undervaluation relative to growth. Revenue grew 15% YoY in Q1 2026, and net margin expanded to 16.7% from 10.2% a year ago. The company generates $1.429B in TTM free cash flow, providing a 5.5% FCF yield. Compared to the industry average PE of 22x, the premium is warranted by superior growth and profitability. Risks & Conditions: Key risks include further revenue deceleration, competitive pressure from Abbott, and macro headwinds. This Buy rating would be downgraded to Hold if revenue growth falls below 10% or if the PE ratio compresses below 25x. Conversely, an upgrade would require sustained growth above 20% and margin expansion. Overall, DexCom appears fairly valued relative to its growth prospects, with potential upside from the pediatric Stelo catalyst.
Sign up to view all
DXCM 12-Month Price Forecast
DexCom's fundamentals are solid with expanding margins and strong cash flow, but the decelerating growth trend and premium valuation warrant caution. The pediatric Stelo expansion is a key catalyst that could re-accelerate growth, supporting a bullish stance. However, the wide analyst target range and high short interest suggest uncertainty. The base case of moderate growth and stable margins is most likely, but the bull case has a realistic chance if execution is strong. We would upgrade to high confidence if revenue growth re-accelerates above 20% in the next quarter.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Dexcom's 12-month outlook, with a consensus price target around $85.46 and implied upside of +9.6% versus the current price.
Average Target
$85.46
0 analysts
Implied Upside
+9.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$65 - $112
Analyst target range
DexCom is covered by 24 analysts, with a consensus recommendation of 'Strong Buy' (mean rating 1.33 on a 1-5 scale). The average target price is $85.46, implying 17.5% upside from the current price of $72.73. The distribution shows 0 holds and 0 sells, indicating strong bullish sentiment. The target range spans from a low of $65.00 to a high of $112.00. The high target of $112 assumes successful pediatric expansion and margin expansion, while the low of $65 reflects competitive risks or slower growth. The wide spread ($47) signals high uncertainty. Recent ratings from Mizuho, Deutsche Bank, and Piper Sandler have maintained positive stances, while Barclays remains Underweight. The overall consensus is bullish, but the wide range suggests caution is warranted.
Bulls vs Bears: DXCM Investment Factors
DexCom presents a balanced risk-reward profile. The bull case is supported by the recent pediatric Stelo expansion, expanding margins, strong free cash flow, and an attractive PEG ratio. However, bears point to decelerating revenue growth, a premium valuation relative to peers, high short interest, and competitive threats. The single most important tension is whether the pediatric Stelo expansion can re-accelerate growth to justify the current valuation. If growth re-accelerates above 20%, the stock could re-rate higher; if growth continues to decelerate, the premium multiple could compress. Currently, the bull case has slightly stronger evidence given the strong financial health and recent catalyst, but the bear case warrants caution.
Bullish
- Pediatric Stelo Expansion: FDA clearance for pediatric use of the over-the-counter Stelo monitor significantly expands DexCom's addressable market into a demographic with rising prediabetes rates, potentially re-accelerating revenue growth from the current 15% YoY.
- Expanding Margins and Profitability: Gross margin improved to 62.9% in Q1 2026 from 59.5% in Q2 2025, and net margin expanded to 16.7% from 10.2% a year ago, demonstrating strong operating leverage and cost control.
- Strong Free Cash Flow Generation: TTM free cash flow of $1.429B provides a 5.5% FCF yield, indicating the company generates ample cash to fund growth internally and return capital to shareholders.
- Attractive PEG Ratio: With a PEG ratio of 0.67, the stock appears undervalued relative to its earnings growth rate, suggesting potential upside if growth expectations are met.
Bearish
- Decelerating Revenue Growth: Revenue growth slowed to 15.0% YoY in Q1 2026 from 20.9% in Q4 2025, indicating a multi-quarter deceleration trend that could pressure the premium valuation.
- Premium Valuation vs. Peers: Trailing PE of 31.0x is 41% above the medical devices industry average of 22x, leaving little room for error if growth disappoints.
- High Short Interest and Volatility: Short ratio of 3.42 days to cover and beta of 1.453 indicate elevated bearish sentiment and market risk, amplifying downside moves.
- Wide Analyst Target Range: Analyst targets range from $65 to $112, a $47 spread, signaling high uncertainty about future performance and potential for negative surprises.
DXCM Technical Analysis
The stock is in a recovery phase after a significant downtrend, with a 1-year price change of -14.2% but a strong 3-month rally of +18.8%. Currently trading at $72.73, it sits at 63% of its 52-week range ($54.11-$89.98), indicating it has bounced from lows but remains well below highs, suggesting room for further upside if momentum persists. The 1-year underperformance relative to SPY (relative strength -35.1%) highlights the prior downtrend, but the recent recovery is noteworthy. Short-term momentum is mixed: the 1-month change is -2.0%, decelerating from the 3-month surge, while the 6-month change is +4.6%. This divergence—strong 3-month rally but recent pullback—could signal a temporary consolidation before the next leg higher or a loss of momentum. The stock's beta of 1.453 indicates 45% more volatility than the market, amplifying both gains and losses. Key support is at the 52-week low of $54.11, while resistance is at the 52-week high of $89.98. A breakout above $89.98 would signal a resumption of the long-term uptrend, while a breakdown below $54.11 would suggest further downside. The current price near the middle of the range offers a balanced risk-reward.
Beta
1.45
1.45x market volatility
Max Drawdown
-38.8%
Largest decline past year
52-Week Range
$54-$90
Price range past year
Annual Return
-7.3%
Cumulative gain past year
| Period | DXCM Return | S&P 500 |
|---|---|---|
| 1m | +6.6% | +0.1% |
| 3m | +21.9% | +5.7% |
| 6m | +12.1% | +8.5% |
| 1y | -7.3% | +20.3% |
| ytd | +17.2% | +10.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DXCM Fundamental Analysis
Revenue growth is solid but decelerating: Q1 2026 revenue of $1.192B grew 15.0% YoY, down from 20.9% YoY in Q4 2025 ($1.260B) and 16.5% in Q3 2025 ($1.209B). The multi-quarter trend shows growth moderating from the 2024 pace, but still healthy. The pediatric Stelo expansion could re-accelerate growth. Gross margin improved to 62.9% in Q1 2026 from 59.5% in Q2 2025, reflecting operating leverage. Net income was $199.5M in Q1 2026, up from $105.4M in Q1 2025, with net margin expanding to 16.7% from 10.2%. Operating margin rose to 21.4% from 12.9% a year ago, indicating strong cost control. The company is solidly profitable with expanding margins. DexCom boasts a healthy balance sheet: debt-to-equity of 0.51, current ratio of 1.88, and TTM free cash flow of $1.429B. ROE is 30.5%, reflecting efficient capital use. The company generates ample cash to fund growth internally, with FCF yield of 5.5% (FCF/ market cap). The low debt-to-equity and strong liquidity suggest minimal financial risk.
Quarterly Revenue
$1.2B
2026-03
Revenue YoY Growth
+15.0%
YoY Comparison
Gross Margin
62.9%
Latest Quarter
Free Cash Flow
$1.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DXCM Overvalued?
Since net income is positive, the PE ratio is the primary metric. The trailing PE is 31.0x, while the forward PE is 23.6x, implying the market expects earnings growth of ~31% over the next year. The gap between trailing and forward PE suggests optimistic growth expectations. Compared to the medical devices industry average PE of ~22x, DexCom trades at a 41% premium (31.0x vs 22x). This premium is justified by superior revenue growth (15% YoY) and expanding margins, but investors are paying up for future growth. The PEG ratio of 0.67 suggests the stock is undervalued relative to its growth rate, indicating potential upside. Historically, DexCom's trailing PE has ranged from 24x to 224x over the past 5 years. The current 31.0x is near the low end of its historical range, suggesting the stock is relatively cheap compared to its own history. This could indicate a value opportunity if growth re-accelerates, or reflect structural concerns about slowing growth.
PE
31.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 23x~223x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: DexCom's revenue growth decelerated from 20.9% YoY in Q4 2025 to 15.0% in Q1 2026, raising concerns about sustained momentum. While the company has a healthy balance sheet with debt-to-equity of 0.51 and TTM free cash flow of $1.429B, any further deceleration could pressure the premium valuation. The net margin of 16.7% is expanding but still below the operating margin of 21.4%, indicating some non-operating drag. Market & Competitive Risks: The stock trades at a trailing PE of 31.0x, a 41% premium to the medical devices industry average of 22x, making it vulnerable to multiple compression if growth disappoints. With a beta of 1.453, the stock is highly sensitive to macro factors such as interest rate changes. The recent FDA clearance for pediatric Stelo is a positive catalyst, but competitive pressure from Abbott's FreeStyle Libre remains a threat. Worst-Case Scenario: If revenue growth decelerates further, competitive pressures intensify, or macro conditions worsen, the stock could fall to the 52-week low of $54.11, representing a 25.6% decline from the current price of $72.73. The analyst low target of $65 implies a 10.6% downside, but a more severe scenario could see the stock retest the 52-week low, resulting in a loss of approximately $18.62 per share.
FAQ
The primary risks are: (1) Financial: decelerating revenue growth (15% YoY in Q1 2026 vs. 20.9% in Q4 2025) could pressure the premium valuation. (2) Competitive: Abbott's FreeStyle Libre and other CGM competitors could erode market share, especially in the OTC segment. (3) Macro: with a beta of 1.453, the stock is highly sensitive to interest rate changes and market downturns. (4) Company-specific: the wide analyst target range ($65-$112) reflects high uncertainty about the impact of the pediatric Stelo expansion. The most severe risk is a growth deceleration below 10%, which could trigger a de-rating to the 52-week low of $54.11.
Based on analyst targets and scenario analysis, the 12-month forecast for DXCM ranges from $54 to $112. The base case (50% probability) targets $75-$85, assuming revenue growth stabilizes around 15% and margins improve. The bull case (30% probability) targets $85-$112, driven by successful pediatric Stelo expansion and growth re-acceleration. The bear case (20% probability) targets $54-$65, if growth decelerates below 10% or competitive pressures intensify. The most likely scenario is the base case, with the stock trading near the analyst average of $85.46.
DexCom's trailing PE of 31.0x is above the medical devices industry average of 22x, suggesting a premium valuation. However, the PEG ratio of 0.67 indicates the stock is undervalued relative to its expected earnings growth rate. Historically, the stock has traded at a wide PE range of 24x to 224x over the past 5 years, and the current 31.0x is near the low end, implying relative cheapness. The market is pricing in continued growth and margin expansion, but any disappointment could lead to multiple compression. Overall, the valuation is fair given the growth prospects, but not a bargain.
DexCom presents a compelling risk/reward for growth-oriented investors. With a consensus analyst rating of Strong Buy and an average target price of $85.46, implying 17.5% upside from $72.73, the stock offers potential appreciation. The PEG ratio of 0.67 suggests it is undervalued relative to its earnings growth, and the recent FDA clearance for pediatric Stelo expands its addressable market. However, the trailing PE of 31.0x is a 41% premium to the industry average, and revenue growth is decelerating. For investors with a long-term horizon and tolerance for volatility (beta 1.453), DXCM is a good buy, but those seeking stable income or low risk should consider alternatives.
DexCom is better suited for long-term investment due to its growth stage, strong competitive position, and expanding addressable market. The company does not pay a dividend, so total return depends on capital appreciation. With a beta of 1.453, the stock is volatile and may experience significant short-term swings, making it less suitable for short-term trading unless one has a high risk tolerance. The recent 3-month rally of 18.8% suggests momentum, but the 1-year decline of 14.2% highlights the risk of holding through downturns. A minimum holding period of 3-5 years is recommended to allow the pediatric Stelo expansion and margin improvements to materialize.